Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412).” Advertisement This Phase II study investigated the … Continue reading Brentuximab Vedotin, Ipilimumab, + Nivolumab Combination Hodgkin Lymphoma [ASH 2023]